Copy to clipboard 
Stryker is introducing its Incompass Total Ankle System, intended for patients with end-stage ankle arthritis. Incompass, which received FDA marketing clearance earlier this year, introduces an innovative implant with an enhanced instrument platform.
Incompass was developed to mimic Stryker’s Infinity and Inbone with a similar implant profile, fixation and sulcus articulation. Leveraging these two legacy designs, Stryker created Incompass, aiming to advance clinical performance, address evolving surgeon needs and deliver meaningful value to hospitals and patients. Both legacy systems have documented five-year survivorship rates of 98% or higher.
The system offers intraoperative flexibility, enabling surgeons to adjust implant configurations in real time to support patient-specific needs. Incompass includes 3D-printed porous metal tibial and talar components engineered to promote early bony ingrowth, often as early as four weeks. By combining implant options and reducing instrumentation, the system helps reduce procedural complexity, enhance decision-making and lower sterilization demands.
The implants were designed using SOMA, Stryker’s Orthopedic Modeling and Analytics tool, which analyzed real patient anatomy from arthritic ankle CT scans in the Prophecy database. SOMA was used to study bone quality and optimize implant location.
Further insights were gained from more than 80,000 Prophecy scans. The system’s instrumentation was refined with input from a global clinical advisory team of experienced foot and ankle surgeons and informed by more than 100,000 total ankle cases.
“Incompass was developed with one goal in mind: to give surgeons more flexibility and confidence in the OR while improving outcomes for their patients,” said Adam Jacobs, VP and GM of Stryker’s Foot & Ankle business. “This advanced system has been fully reimagined by the insights of countless surgeons, engineers, and real-world use cases built on 20 years of experience. We’re proud to continue leading the way in total ankle innovation and help shape what’s next for ankle arthroplasty.”
Source: Stryker
Stryker is introducing its Incompass Total Ankle System, intended for patients with end-stage ankle arthritis. Incompass, which received FDA marketing clearance earlier this year, introduces an innovative implant with an enhanced instrument platform.
Incompass was developed to mimic Stryker’s Infinity and Inbone with a similar implant...
Stryker is introducing its Incompass Total Ankle System, intended for patients with end-stage ankle arthritis. Incompass, which received FDA marketing clearance earlier this year, introduces an innovative implant with an enhanced instrument platform.
Incompass was developed to mimic Stryker’s Infinity and Inbone with a similar implant profile, fixation and sulcus articulation. Leveraging these two legacy designs, Stryker created Incompass, aiming to advance clinical performance, address evolving surgeon needs and deliver meaningful value to hospitals and patients. Both legacy systems have documented five-year survivorship rates of 98% or higher.
The system offers intraoperative flexibility, enabling surgeons to adjust implant configurations in real time to support patient-specific needs. Incompass includes 3D-printed porous metal tibial and talar components engineered to promote early bony ingrowth, often as early as four weeks. By combining implant options and reducing instrumentation, the system helps reduce procedural complexity, enhance decision-making and lower sterilization demands.
The implants were designed using SOMA, Stryker’s Orthopedic Modeling and Analytics tool, which analyzed real patient anatomy from arthritic ankle CT scans in the Prophecy database. SOMA was used to study bone quality and optimize implant location.
Further insights were gained from more than 80,000 Prophecy scans. The system’s instrumentation was refined with input from a global clinical advisory team of experienced foot and ankle surgeons and informed by more than 100,000 total ankle cases.
“Incompass was developed with one goal in mind: to give surgeons more flexibility and confidence in the OR while improving outcomes for their patients,” said Adam Jacobs, VP and GM of Stryker’s Foot & Ankle business. “This advanced system has been fully reimagined by the insights of countless surgeons, engineers, and real-world use cases built on 20 years of experience. We’re proud to continue leading the way in total ankle innovation and help shape what’s next for ankle arthroplasty.”
Source: Stryker
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
